Login to Your Account

In The Clinic NEWS

Exelixis Inc.'s MEK-inhibitor cobimetinib, given in combination with Roche AG's Zelboraf, significantly improved OS vs. Zelboraf alone for previously untreated patients with unresectable locally advanced or metastatic melanoma.

HONG KONG – With a nod to proceed from the Korea Food and Drug Administration, Seoul-based Kainos Medicine Inc. is taking its Parkinson's disease candidate, KR-33493, into the clinic.

Arrowhead Research Corp. reported new top-line data on its lead RNAi therapy ARC-520, demonstrating that it achieved significant hepatitis B virus (HBV) surface antigen reductions during a phase IIa study, particularly in treatment-naïve patients who tested positive for HBV e-antigen.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: